Seeking Alpha

Geron (GERN) says it has discontinued development of its GRN1005 brain cancer drug following...

Geron (GERN) says it has discontinued development of its GRN1005 brain cancer drug following disappointing Phase II trial results. The company says it will focus on the development of its imetelsat cancer drug, and will cut 43 full-time positions as part of a restructuring. Geron expects to achieve annual savings of $32M from the restructuring, and record charges of $6M. Shares are halted, and will resume trading at 4:35PM ET.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|